文献速递前列腺癌男科与性医学

跨性别女性前列腺癌筛查差异:MarketScan数据库分析

Disparities in Prostate Cancer Screening for Transgender Women: An Analysis of the MarketScan Database.
PubMed 文献 · Urology · 2023-03-25

本研究利用IBM MarketScan数据库识别2013—2019年符合条件的跨性别女性2957例,并与资格相近的顺性别男性比较PSA筛查比例。结果显示40—54岁和55—69岁跨性别女性PSA筛查率显著低于顺性别男性,而70—80岁组则更高(所有P<.001)。作者认为这是首个评估有保险跨性别女性PSA筛查率的研究,需进一步调查以实现公平医疗。

要点

  • 40—54岁和55—69岁跨性别女性PSA筛查率显著低于顺性别男性(P<.001)。
  • 70—80岁跨性别女性PSA筛查率高于顺性别男性(P<.001)。
  • 目前尚无跨性别女性PSA筛查的正式指南,缺乏数据指导临床实践。

核心结论

  • 70岁以上跨性别女性PSA筛查率较高,但其他所有年龄组的总体筛查率低于该数据集中的一般人群。
  • 需进一步调查以为跨性别群体提供公平医疗。

研究设计与样本

  • 利用IBM MarketScan数据库,以ICD编码识别跨性别女性队列,按2013—2019年逐年确定纳入资格。
  • 每年要求连续入组、跨性别诊断后随访3个月、年龄40—80岁且无前列腺恶性肿瘤既往诊断。
  • 该队列与资格标准相似的顺性别男性进行比较,采用对数二项回归比较PSA筛查比例。

主要发现

  • 共有2957例跨性别女性符合纳入标准。
  • 40—54岁和55—69岁跨性别女性PSA筛查率显著低于顺性别男性(P<.001)。
  • 70—80岁跨性别女性PSA筛查率高于顺性别男性(P<.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe the prevalence of PSA screening amongst transgender women. A transgender individual is someone whose gender identity differs from their birth sex or the societal norms of that assigned sex. There are no formal guidelines regarding PSA screening in transgender women, even though they retain prostatic tissue throughout the gender-affirming process, and there is a lack of existing data to adequately inform clinical practice. METHODS: We identified a cohort of transgender women in the IBM MarketScan dataset using ICD codes. The patient...s eligibility for inclusion was determined on an annual basis for the years 2013-2019. For each year, we required continuous enrollment, 3 months of post-transgender diagnosis follow-up, and aged 40-80 without a prior diagnosis of prostate malignancy. This cohort was compared to cisgender men with similar eligibility criteria. The proportions of individuals undergoing PSA screening were compared using log-binomial regression. RESULTS: A group of 2957 transgender women met the inclusion criteria. We saw significantly lower PSA screening rates among transgender individuals for ages 40-54 and 55-69, but higher rates within the age group 70-80 (P.ß<.ß.001 for all). CONCLUSION: This is the first study evaluating PSA screening rates for insured transgender women. While the rates for screening in transgender women over the age of 70 are higher, the overall rate of screening for all other age groups lags below the general population in this dataset. Further investigation is necessary to provide equitable care for the transgender community.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Premo H, Gordee A, Lee HJ, et al. Disparities in Prostate Cancer Screening for Transgender Women: An Analysis of the MarketScan Database. Urology. 2023. PMID: 36972765. doi:10.1016/j.urology.2023.03.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。